Mr. Barry O'Leary:

Regeneron has not issued any further statement in that regard. Its initial statement was made in the past couple of weeks. Regeneron is one of a number of next wave biopharma companies and would be a very attractive win. However, there are many hurdles one has to jump in winning large investments. At this stage, I can only comment on the status of the project from a public point of view.